HTTP 200 OK
Allow: GET
Content-Type: application/json
Vary: Accept
{
"url": "https://lda.senate.gov/api/v1/filings/9637fc11-c7ff-4b74-9da2-8d816bd73eb0/?format=api",
"filing_uuid": "9637fc11-c7ff-4b74-9da2-8d816bd73eb0",
"filing_type": "Q2",
"filing_type_display": "2nd Quarter - Report",
"filing_year": 2021,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/9637fc11-c7ff-4b74-9da2-8d816bd73eb0/print/",
"filing_document_content_type": "text/html",
"income": "30000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Daniel Faraci",
"dt_posted": "2021-09-08T10:21:17.203000-04:00",
"termination_date": null,
"registrant_country": "United States of America",
"registrant_ppb_country": null,
"registrant_address_1": "P.O. Box 65459",
"registrant_address_2": null,
"registrant_different_address": false,
"registrant_city": "Washington",
"registrant_state": "DC",
"registrant_zip": "20035",
"registrant": {
"id": 40044351,
"url": "https://lda.senate.gov/api/v1/registrants/40044351/?format=api",
"house_registrant_id": 39942,
"name": "GRASSROOTS POLITICAL CONSULTING LLC",
"description": "political consulting company",
"address_1": "P.O. Box 26042",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "Alexandria",
"state": "VA",
"state_display": "Virginia",
"zip": "22313",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "MR. DANIEL FARACI",
"contact_telephone": "+1 202-642-3977",
"dt_updated": "2026-03-02T18:43:24.813625-05:00"
},
"client": {
"id": 209268,
"url": "https://lda.senate.gov/api/v1/clients/209268/?format=api",
"client_id": 140,
"name": "REVIVE THERAPEUTICS INC.",
"general_description": "pharmaceutical and therapeutics manufacturer",
"client_government_entity": false,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "CA",
"country_display": "Canada",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "CA",
"ppb_country_display": "Canada",
"effective_date": "2021-04-01"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Advocating for assistance w/Phase 3 trial for Bucillamine",
"foreign_entity_issues": "Canadian company listed on CSE",
"lobbyists": [
{
"lobbyist": {
"id": 40330,
"prefix": null,
"prefix_display": null,
"first_name": "DANIEL",
"nickname": null,
"middle_name": null,
"last_name": "FARACI",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 139,
"name": "Natl Institutes of Health (NIH)"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
}